{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:18Z","timestamp":1786984278321,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022110","name":"bioM\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ahj.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T12:30:22Z","timestamp":1453552222000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial"],"prefix":"10.1016","volume":"175","clinical-trial-number":[{"clinical-trial-number":"nct00968708","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yuichi J.","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faeiz","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Pt 1","key":"10.1016\/j.ahj.2016.01.011_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0002-8703(00)90311-9","article-title":"Predictors of readmission among elderly survivors of admission with heart failure","volume":"139","author":"Krumholz","year":"2000","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.ahj.2016.01.011_bb0010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","article-title":"Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry","volume":"77","author":"Shindler","year":"1996","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1479164112471064","article-title":"Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology","volume":"10","author":"Cubbon","year":"2013","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/dc12-2625","article-title":"Economic costs of diabetes in the U.S. in 2012","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ahj.2016.01.011_bb0025","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMp0805758","article-title":"Assessing the cardiovascular safety of diabetes therapies","volume":"359","author":"Goldfine","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ahj.2016.01.011_bb0030","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ahj.2016.01.011_bb0035","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.011_bb0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2007.03.029","article-title":"Peroxisome proliferator\u2013activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization\u2014results of the PPAR study","volume":"154","author":"Bhatt","year":"2007","journal-title":"Am Heart J"},{"issue":"9493","key":"10.1016\/j.ahj.2016.01.011_bb0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"9593","key":"10.1016\/j.ahj.2016.01.011_bb0050","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.011_bb0055","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.ahj.2016.01.011_bb0065","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.113.008221","article-title":"Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus","volume":"129","author":"Menon","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2016.01.011_bb0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/157339910793499119","article-title":"Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus","volume":"6","author":"Ghatak","year":"2010","journal-title":"Curr Diabetes Rev"},{"issue":"14","key":"10.1016\/j.ahj.2016.01.011_bb0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2016.01.011_bb0080","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2337\/dc14-2868","article-title":"Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0085","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0090","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"White","year":"2011","journal-title":"Am Heart J"},{"issue":"9982","key":"10.1016\/j.ahj.2016.01.011_bb0095","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ahj.2016.01.011_bb0100","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.2337\/diacare.27.suppl_2.B27","article-title":"The burden of diabetes-associated cardiovascular hospitalizations in veterans administration (VA) and non-VA medical facilities","volume":"27","author":"Smith","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.ahj.2016.01.011_bb0110","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1007\/s00592-003-0120-0","article-title":"Epidemiology of cardiovascular complications in type 2 diabetes mellitus","volume":"40","author":"Meigs","year":"2003","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0115","first-page":"714","article-title":"Relationship of diabetes with cardiovascular disease-related hospitalization rates, length of stay, and charges: analysis by race\/ethnicity, age, and sex","volume":"17","author":"Cook","year":"2007","journal-title":"Ethn Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.ahj.2016.01.011_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.ahj.2016.01.011_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.011_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1755-5922.12075","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants","volume":"32","author":"Wu","year":"2014","journal-title":"Cardiovasc Ther"},{"issue":"14","key":"10.1016\/j.ahj.2016.01.011_bb0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2016.01.011_bb0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.011_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.09.078","article-title":"Cost-effectiveness of revascularization strategies: the ASCERT study","volume":"65","author":"Zhang","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2016.01.011_bb0155","first-page":"769","article-title":"Costs of heart failure\u2013related hospitalizations in patients aged 18 to 64 years","volume":"16","author":"Wang","year":"2010","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.011_bb0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.22341","article-title":"Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than medicare payments","volume":"38","author":"Afana","year":"2015","journal-title":"Clin Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:08Z","timestamp":1762077368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":29,"alternative-id":["S0002870316000260"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}